|Authors||Greenberg CC, Bafford AC, Golshan M|
|Journal||Expert Rev Anticancer Ther Volume: 8 Issue: 2 Pages: 195-8|
|Publish Date||2008 Feb|
The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axillas. With the increased use of SLNB in women who present with breast carcinoma, the role of completion ALND for a positive sentinel lymph node has been challenged. We review the literature available and discuss future directions in identifying a subgroup who may avoid an ALND.